Amplia Therapeutics Successfully Raises $13 Million via Share Allotment

2 min read | November 07, 2024 03:41 PM AEDT | By Team Kalkine Media

Google News:

Amplia Therapeutics Successfully Raises $13 Million via Share Allotment — Image source: Shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

Highlights:

Amplia Therapeutics Ltd. successfully raised $13 million through an institutional placement.
Over 67 million shares were allotted at a price of $0.115 each, strengthening the company’s financial position.
The company is advancing its research and clinical trials, focusing on its promising cancer drug, narmafotinib, and FAK inhibitors.

Amplia Therapeutics Ltd. (ASX:ATX) has completed the allotment of more than 67 million shares through an institutional placement, raising a total of $13 million. This capital raise is a significant development for the company, enhancing its financial capacity as it continues to progress with its research and clinical trials, particularly in the area of cancer treatment.

The raised funds will primarily support the ongoing development of Amplia's leading drug candidate, narmafotinib, which is a promising treatment in the field of oncology. Narmafotinib, a potent FAK (focal adhesion kinase) inhibitor, is being tested for its potential to target and disrupt cancer cell growth, making it a key component in the company's strategic focus on FAK inhibitors. These inhibitors are emerging as an innovative class of drugs with the potential to treat a variety of cancers, positioning Amplia therapeutically in a growing segment of the oncology market.

The institutional placement, which involved the allotment of shares at a price of $0.115 each, strengthens Amplia's financial position, enabling the company to advance its clinical pipeline and further explore the therapeutic potential of narmafotinib. As the company continues its research, it will also look to expand its understanding of FAK inhibition and its broader application in cancer treatment.

Amplia’s commitment to advancing its research in cancer therapies, combined with its focus on FAK inhibitors, places it in an advantageous position within the evolving oncology market. The company’s strategic focus, alongside the capital raised, provides a solid foundation to support its clinical development and long-term goals in the biopharmaceutical sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.